Can a personalised mRNA vaccine fight melanoma? Russia's first patient completes treatment

Can a personalised mRNA vaccine fight melanoma? Russia's first patient completes treatment

Oncology

Melanoma is an aggressive form of skin cancer with a high potential for invasion and metastasis. Unlike basal cell carcinoma (BCC), which rarely metastasises, melanoma is associated with a greater risk of disease progression and distant spread. Globally, it accounts for approximately 324,635 new cases and 57,043 deaths, highlighting its significant disease burden. Against this background, personalised messenger RNA (mRNA) vaccines are emerging as a promising therapeutic approach designed to stimulate tumour-specific immune responses. Russia's reported completion of treatment in its first patient receiving a personalised mRNA cancer vaccine marks an important development in exploring this approach for melanoma management.[1]What just happened?A Russian patient with advanced melanoma has finished a course of a personalised mRNA vaccine that Russia's Health Ministry approved in 2025, and he received his first dose in April 2026.[2] About four months after the course ended, his doctors report that he feels well and shows no new tumours.[3] Because this is one patient described in official statements, it is a hopeful early signal, not proof that the vaccine works.What are the key facts?QuestionAnswerWhat is it?A vaccine made for one patient from the genetic makeup of that person's own tumourWho developed it?Gamaleya Research Institute, MoscowWho received it first?A 60-year-old man with stage III melanoma that had spreadWhere was he treated?Herzen Moscow Oncology Research InstituteHow is he followed up?Monthly body scans, with observation for three yearsWhy does this matter?Rather than simply treating the disease, this vaccine aims to teach the patient's own immune system to find and destroy the cells that pose a threat.[2] Russia's Health Ministry approved it in 2025, together with a personalised peptide medicine for colorectal cancer.[2]How does It work?It is built for one person at a time. Doctors analyse the genetic makeup of the patient's tumour and of healthy tissue, then use that analysis to create a custom vaccine meant to train the immune system to recognise and attack cancer cells.[2] The institute's scientific director likened it to tuning the body's own defences, and cautioned that there is no universal cure, because every tumour is unique.[3]How did the first patient respond?The patient is a 60-year-old man whose melanoma, a serious type of skin cancer, had reached stage III and spread.[2] The reports so far are below, newest first.WhenWhat was reportedNovember 2026Course completed. About four months later, no signs of new tumoursJuly 2026Feels well and has developed the immune response needed to fight the disease. Two further doses expectedApril 2026First dose given at the Herzen Moscow Oncology Research InstituteWhat does no new tumours mean?It means recent examinations found no fresh tumour growth.[3] It does not mean the cancer can never return, which is why he has monthly high-resolution CT scans at the National Medical Research Center for Radiology, with close attention to the lymph nodes, and will be observed for the next three years.[3]What comes next?Personalised vaccines were being prepared for ten more patients as of July 2026[2]The Gamaleya Institute is also working on treatments for pancreatic, kidney and non-small cell lung cancer[2]Kazakhstan is developing its own anti-cancer drug, with large-scale production planned for mid-2027[3]Can we say the vaccine works?Only one patient. One person's result cannot show how well the vaccine works for others, and there is no comparison groupOther treatments may have played a part. The reports do not say whether he also had other cancer treatment. If he did, the credit cannot go to the vaccine aloneFew details. The reports describe a general immune response but give no laboratory detail, safety information or definition of cancer recurrenceA short wait. Four months is not long enough to know whether melanoma will returnNot yet independently reviewed. The findings come from official statements reported by news outlets, not from a peer-reviewed study[2][3]What Is the bottom line?This is a promising first data point, not a proven treatment. To know whether personalised mRNA vaccines work, researchers will need larger, controlled studies that track how long patients stay cancer-free and how long they live, along with immune testing and open reporting of side effects.Reference(s):1. Wang M, Gao X, Zhang L. Recent global patterns in skin cancer incidence, mortality, and prevalence. Chin Med J (Engl). 2025;138(2):185-192. doi:10.1097/CM9.0000000000003416. https://pmc.ncbi.nlm.nih.gov/articles/PMC11745855/2. https://iol.co.za/lifestyle/health/2026-07-31-russian-cancer-vaccine-shows-positive-early-results/3. https://kz.kursiv.media/?p=7172127